<SEC-DOCUMENT>0001193125-15-373459.txt : 20151111
<SEC-HEADER>0001193125-15-373459.hdr.sgml : 20151111
<ACCEPTANCE-DATETIME>20151110161500
ACCESSION NUMBER:		0001193125-15-373459
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20151110
FILED AS OF DATE:		20151110
DATE AS OF CHANGE:		20151110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		151219106

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d83358d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited&nbsp;</B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 10&nbsp;November 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g83358logo_new.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">424 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr&nbsp;Ian Phillips MNZM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim Chairman</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting CEO</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10 November 2015</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRECLINICAL STUDIES JUSTIFIES MODE OF DELIVERY AND DOSING REGIMEN FOR ANISINA</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intravenous Anisina drug product identified</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Efficacy in a
preclinical model of neuroblastoma as monotherapy and in combination using IV delivery is retained</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anisina safety assessment program has commenced</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fort Lauderdale FL, November 10, 2015</B>: US-Australian drug discovery company,
Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of preclinical studies which confirm the efficacy of the lead anti-tropomyosin (ATM) compound, Anisina, when delivered using a clinically relevant formulation, mode of administration
and dosing regimen.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Presenting at the &#145;American Association for Cancer Research
Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship&#146; conference in Fort Lauderdale, Florida today, Justine Stehn PhD, Novogen Anti-Tropomyosin Program Director, said &#147;These data validate the
strategic decision to develop the Anisina drug candidate. We have shown that intravenously administered Anisina dosed less frequently in a preclinical study retained anti-cancer activity as a monotherapy, and enhanced the efficacy of a drug commonly
used to treat pediatric neuroblastoma&#148;.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Based on these data we have now identified the Anisina drug candidate to be progressed into preclinical safety studies,
and, pending successful completion of those safety studies, into our clinical development programs in adult and pediatric indications,&#148; Dr Stehn said. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lead Investigator Dr Timothy Cripe MD, PhD, from Nationwide Children&#146;s Hospital, Columbus Ohio, said &#147;This is a key proof-of-concept study and
confirmed the clinical potential for this class of drug in the treatment of neuroblastoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This class of compounds now has the potential to improve
the effectiveness of standard-of-care chemotherapeutics such as vincristine (VCR),&#148; Dr Cripe said. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g83358bottom_new.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g83358top_new.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background Detail </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anisina belongs to a unique &#145;first in class&#146; family of compounds which target the cytoskeleton of a cancer cell. Previously the Company has
highlighted that Anisina has activity <I>in vitro</I> against a diverse panel of both adult and pediatric tumor cells and is effective as a monotherapy in reducing tumor growth in preclinical models of cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The real novelty and potential of this class of compound lies in their ability to enhance the effectiveness of standard-of-care microtubule inhibitors
belonging to the taxane and vinca alkaloid families as observed preclinically. This enhanced activity has been observed <I>in vitro</I> in both adult (prostate) and pediatric (neuroblastoma) cancer types. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A recent study conducted by Dr Cripe demonstrated in a preclinical animal model of neuroblastoma that intraperitoneally delivered Anisina, when used in
combination with vincristine, resulted in a significant regression of tumor growth in ~60% of animals treated. This translated to a significant improvement in median survival with one animal from this treatment group having no measurable tumor 100
days post treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whilst very informative, the initial proof-of-concept combinatorial study had limitations in that Anisina was delivered daily via
intraperitoneal injection and this mode of delivery is not practical in a clinical setting. Today&#146;s announcement concerns the important key step of validating the acceptable mode of delivery and dosing regimen of Anisina. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this study, the, circulating blood levels of Anisina were measured after the delivery of the drug by either an intravenous (IV) or oral (PO) route. The
level and length of time Anisina remained in the blood was significantly higher when delivered by IV compared with oral. The efficacy of Anisina delivered IV in combination with vincristine was evaluated in a preclinical model of neuroblastoma in
collaboration with Dr Cripe&#146;s group at Nationwide Children&#146;s Hospital. In this study, animals with tumors were treated with: i) no drug (Control), ii) vincristine alone (05.mg/kg, 1x/week, IV), iii) Anisina alone (60mg/kg, 2x/week, IV) and
iv) VCR (05.mg/kg, 1x/week, IV) + Anisina (60mg/kg, 2x/week, IV). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Again the combined treatment group showed a significant reduction in tumor growth
(&gt;90% at day 14) compared to no drug control and prolonged survival compared to either drug alone. Additionally Anisina alone, significantly retarded tumor proliferation (~50% at day 14) compared to control. This study confirms that it is
possible to deliver Anisina using a clinically relevant formulation, reduced dosing schedule and mode of delivery without any impact efficacy. An additional key finding was that the Anisina doses as a monotherapy and in combination was well
tolerated <I>in vivo</I> as no significant change in percentage body weight was observed in these treatment groups compared to no drug controls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g83358bottom_new.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g83358top_new.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In parallel Novogen is progressing very smoothly with the large-scale manufacture of the drug substance and
drug product required for clinical trials. The Company is currently on track to commence a first-in-human safety study later in 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Anisina
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anisina is a small molecule which belongs to a family of compounds termed the anti-tropomyosins or ATMs. Anisina has been designed to inhibit a
protein known as Tpm3.1. Tpm3.1 is a structural protein and is an indispensable component of the actin microfilaments which make up the cytoskeleton of the cancer cell. By binding to Tpm3.1, Anisina impacts the function of this structural protein
causing the collapse of the cytoskeleton which results in the death of the cancer cell. Anisina has been shown to be effective against a broad range of cancer types. Novogen&#146;s current strategy is to develop Anisina as an adjunct therapy to
improve the effectiveness of standard-of-care microtubule targeting agents, which are used for a large number of both adult and childhood cancers. We are currently focused on the clinical development of Anisina for the treatment of prostate cancer
and neuroblastoma. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Neuroblastoma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuroblastoma is the most common solid tumor in children outside the brain. It is most frequently observed in the young with more than 90% of diagnoses
occurring in children under 5 years of age. Although childhood cancers such as neuroblastoma are relatively rare compared to adult cancers, the emotional burden and the potential years of life lost due to this cancer are substantial making it
essential that new clinical strategies are developed to treat this disease. We believe this approach of targeting the actin to enhance the effect of existing standard-of-care chemotherapeutics represents a very promising and novel therapeutic
strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a
public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc., a joint venture company with Yale University. Novogen has two drug
technology platforms [the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)] yielding drug candidates that are first-in-class with potential application across a range of degenerative diseases. Given the encouraging data from <I>in vitro</I> and
<I>in vivo</I> preclinical proof-of-concept studies in the field of oncology, our immediate focus is to undertake their respective toxicology programs. Our target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma
(DIPG) for Trilexium. While the initial target pediatric indication for Anisina has been identified as neuroblastoma, we are yet to identify the adult indication and are intending to open an all-comers Phase 1 trial initially based on our
preclinical studies. For more information, please visit <U>www.novogen.com </U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g83358bottom_new.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g83358top_new.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kym Robins </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketing and Communications Director, Novogen Group
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E: <U>Kym.Robins@novogen.com</U> / Ph: +61 (0)&nbsp;2 9472 4109 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release
contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such
words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148;
&#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company&#146;s
drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company&#146;s drug development program, including, but not limited to, Anisina, and any other statements that are not historical
facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the
Company&#146;s drug components, including, but not limited to, Anisina, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#146;s drug
compounds, including, but not limited to, Anisina, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company&#146;s intellectual property or trade secrets, including, but not limited to, the
intellectual property relating to Anisina, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are
based on management&#146;s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those
forward-looking statements as a prediction of actual future results. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g83358bottom_new.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g83358bottom_new.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g83358bottom_new.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ .@+& P$1  (1 0,1 ?_$ ,H  0 !!0$! 0$
M       % @,$!@<( 0D* 0$  @,! 0$             ! 4! P8"!P@0  $#
M @$%"0D+"08& P    $  @,$!1$A,1(3!D%18=$RDC-3!W&!D:$B8G(4%4*R
M(W.3TS24-38(L5*"0X-4M%4W\,'")'1%TF.SA'65%D9V$0 " 0("!0D$!P<#
M!0       0(#!!$Q(5&1$@5!87&!H3(3,P:QP5(T\-$B0G*R->%B@I)#<P>B
M@Q3"(U,D=/_:  P# 0 "$0,1 #\ _N,UTO6R<]W&@&NEZV3GNXT UTO6R<]W
M&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT UTO6R
M<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT UL
MV?628#.=-V [N5 :Q?\ :RR6FCJA7WVD@D$62(56NJ,=)N00P&672[RV1I59
M]V+P(E:_LK?SJL$]6.+V+2<2N/;%9J;%MOBNER=E >7>I08[F69SYB,?,4B-
ME5>F3214UO4=I#10C.H_Y5VZ>PT6X=L.U%3BVA;2VQAR LUM7/A\94N,6/<C
M"D1LJ4>\W)[/855;U%>ST4E"G'HWGM>CL-'K]JMI;H[2N%]NE3EQ#'5DS(FG
M<T88G1Q-PX I$:5.'=BD5-:\NKAXUJDY=>C8M!&>T;C^_P!;]:G^<6S!:D:?
M$J?%+:Q[1N/[_6_6I_G$P6I#Q*GQ2VL>T;C^_P!;]:G^<3!:D/$J?%+:Q[1N
M/[_6_6I_G$P6I#Q*GQ2VL>T;C^_UOUJ?YQ,%J0\2I\4MK'M&X_O];]:G^<3!
M:D/$J?%+:Q[1N/[_ %OUJ?YQ,%J0\2I\4MK'M&X_O];]:G^<3!:D/$J?%+:S
M*I+_ 'R@E$U'>;I32C#RXJZI:3AF!^$P<. XA>94X26$DFCW3N+BE+?I3G&7
M,V;M0=K6V%'HBHJXKG&,,16L<)2/CZ9T#R>[I*/*SHO+%/F+6CQ_B%+ON-2/
M[RT[5@;S;^V>BE+672@N%&< '34E2*N('=.KD,$P'.*C2L9KN-,M:/J6@]%>
MG*+UQ>\MFA^TWJW[=;.W/1%+?X6R.R"&KFDHIL=[0J=6"3P$K1*A6AG%X;2U
MH\5X?<:*=6*>J7V7VX&SMJ)G-#VSR.8<H>V5SFD',0YKBTXK26"TK%9#7S]=
M+\H_C0#7S]=+\H_C0#7S]=+\H_C0#7S]=+\H_C0#7S]=+\H_C0#7S]=+\H_C
M0#7S]=+\H_C0&U6::8T;L99#\*_.]V]'PH"5UTO6R<]W&@&NEZV3GNXT UTO
M6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT
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ME0O;9]Z.Z^A,HKCTWQJEIH5O%7-.47L;P[3G]RI]O;/B;D=J*1@)&MDJ;BZ
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M%2"G3:<'DUD7%@]! $ 0&UV8849)W97X<.&KS>! 2J ( @" ( @" ( @" (
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MD2R\&\("4M/TD_%N_*$!LB ("IN9_HCW[4!2@" ( @" ( @" (#Z 2< "3O
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MA98!L9:3++)(=.NQ:T!C3_GJ@9\7.P\"J+OSY?3D.^X%^F0Z9?FD=*CH:2+
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M02 X%E933TSL=X:YC [O8J5&<9K&+3125:%>@]VO"<)?O)KVF&O1J" ( @"
M( @" ( @" ( @/A(&<@=U 2E%9;O<2!16ZKJ <NFV%S8OEI R(>%:Y5:<.\T
MB31L[JX\FG.2Z-&UZ#;*3LXOT[0ZHDH:''W$LSII!W6T['L'.4>5[2B\%BRS
MI\ O9K&HX0Z7B^Q/VGRK[.;_ $XTJ=]%7[S(9C#*[@:RH;&TG])9C>TI9XHQ
M5X!>PTTW"?0\'V_6<OV_['^TO;.ST]HV=V1N5;6LN]+/()334--' V"K8Z=U
M973T],8FND&5KG'+F4ZTO[2A4=2K-*.Z^?L6DYGCWICC_$[6-M96M25554WC
MA%);LECO2:6QC9+\".WE>^&;;/:K9_9FE.BZ:DM(GVANH9G=&UVC0VR*7#)C
MK96@[A7JOZAMX:*$)2EK?V5[WV(C\-_Q#QBLU+BEQ1MZ?*H8U)]'W8I];/T.
M[-NS79;LIV8@V5V3I98J-DKJNMK*N03W&[7&5K&35]PG:R-CYGMC:UK6M;'&
MQH:T !<S=W=:]K.M6>EY+D2U(^U\"X#P[T[8+AW#8M4D\7)O&4Y/.4GHQ?,D
MDEH2P-^48N0@" ( @*FYG^B/?M0%* ( @*'O9& 7N#0<V.[W!G* Q75K!R6.
M=OX^2/[R@+#JV4\D-8. 8D=\XCQ(#&=)(\XN>X]_)X,R H0! ?'M;(PQRM;)
M&1@8Y&MD81O%CP6D=Y$VM*S,-*2W9)..IY&N3['[+5,WK$U@MCI<<2YM.(FN
M.?%T<19$X]UJVJO66A2>!"EPSATY[\J-/>Z/<M!-14E+1021T=+34D8BD 92
MP14[<-!VY$UN*\;TI2^TV]))C2IT8.-*,8K#D27L.-*>LCG'F%DP$ 0! $ 0
M! $ 0!8,EB:EIJCIJ>&3A<QNESP [QKTI263-4Z-*IWXQ?414VS]!)B8C- [
MS7ZQG-DQ/@(6Q5IK/!D2?#:$NYC%[?:14VSE4W$PS0S#<#M*)_CTV>,+VJT>
M701)\,K)8PE&79^PA:BEJ*5^KJ(GQ.W-(9'#?:X8M<.X5M4E+(@U*52E+=J)
MIEA9-80! $ .0%QR-&=QR-'=<< $&*6EY 90'#*TY0X96D;X(R$(.?D" ]3=
MFGW,M7QE?_'U*I[OSW].1'?<"_3*?7^:1O:CEN$ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $!3(]D4;I9GLAB;E=+*]L431ONDD+6-'=*+3H69B345O2T17*S0;
MSVJ]GU@<YM=M-033QXXTEL<^Z5)(')#:%LT;7>DYJE4[*YJ]V#PY]'M*:Z]0
M\%M&XU;B#FN2/VW_ *<5M9JE5VG4$S6SVVVU4S:A@GB=7.;2>1,-8S2A9KI
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M^G25EQZ?X1<Z945">N#W>Q:.PYO=.P.G=I/LFT$L60EM/=:5LS<=P>M4AC<
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M+S'H^%5\.OJ.ON_+7E9?>SZCFLO+=T>?]3T?Z/ I*R.?EWGEGR9=1;63 0!
M7:;IV=/RA]%^D;G1^=O+#R/4.^L^K/J.[;+_ $5OWCY/^\]%^R4"KWON]1UM
MAY?]?^/W&UK26(0$1M%]FR?8/(=]Y_L[-^5;*7>^]_#F1;[R'Y/^[W#Q+M;]
MJ3?=;EN^ZWT//N\*OZ/=^_\ Q'RCB/S#^7S?D]TU9;RO" ( @ SK#R,K,[UV
M=?=MO1_3ZOH^5RF]+YWYOFX*JO?.Y?=U':\!_3E^.7MY?=S&]#..[NYN^H9<
M&U6CDC[+_1^D[GC7B63SS+.TR_I]69LIS[O?SK46!\0! $!6S/WO[P@+J (
<@).V=.[XIV;TV<K^Y 3J ( @*FYG^B/?M0'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g83358logo_new.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g83358logo_new.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ C +& P$1  (1 0,1 ?_$ -$  0 !! ,! 0
M       %! 8'" $#"0(* 0$  04! 0$!            !0$" P0&!P@)"A
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MN_$+BD$>X0UH4IM6AT]Z>.K48:](.J^P5GM8]R[MW1[7]!%YNKXF%6+?/?\
MJKZ7N7M]!@'(LVOF2*+<MX1X 7S-VZ+JB.-/84ZHZN2'1]THZ=@%2=K'MVMJ
MVR[3C\W5,K.=+CY;/U5N]?%^LM+4]I])K,1PU/:?2: :GM/I- -3VGTF@&I[
M3Z30#4]I])H!J>T^DT U/:?2: E[1?KK8Y0EVN6[&>.B5@$+:>0#KW;[2DE#
MK9/41YM*LN6XW(\LE5&QC95_$N>;CR<9_,^]<3.F-[I6VY%J+?$(M4Q6B$RD
MDFVOJZ-2HZN1%*)Z%ZH_K5'7<2<-L-J^<ZS"U^Q>^[RUY=WM_=?ZO7L])E-"
MDK0E:%)6A:0I"T*"T+2>(4A:=4K2>HC@:T]VQ[SH$TTFMJ9]4*B@% * 4 H!
M0"@% 719"?=7!J=._5U__&W0$SJ>T^DT U/:?2: :GM/I- -3VGTF@&I[3Z3
M0#4]I])H!J>T^DT U/:?2: :GM/I- -3VGTF@&I[3Z30#4]I])H#Y4X$)*E+
MY4I&I).@ H"-?N)XI8YAU%:^G_A3U<>V@(PK6HE2E*))U)).NM <:GM/I- -
M3VGTF@&I[3Z30#4]I])H!J>T^DT*K>:?Y@ <KR,G_P"\3?QIJ;L?R8_91YGJ
M7-_R5Z*=/O'[2W-!V5E-.D_K,QUF.V&.9?WLI:'+7>E@!-VA>V\H#1"9L4D-
M2TCM]5P#H56WCYMW'\*H[78_H? Y[5^FM/U6MV5;>:U[\>/VENE\S])AC_L%
MF,&9S7U]F'8^\ 9ND7G><G!7%*&8K@2J&Z0/[_0 ^SS5(/5;$XTMIN[V/AZ^
M/J..70VJVKM<R4885=DUM<NZ/[K^UZJF7+!B]EQF.6+3%[I;@'O$IU1>F2BG
MH+[RN) /0E(2D'H%:-V[<O2YKCKV+@CJL'3L33K;MXL:5WM[92[W]&Q%P58;
MPH!0"@% * 4 H"S,GP2Q90%/2FW(ERY ENZ0SRR/5&B$R&S^"EM)^Y4 0.@B
ML]G(NV-D76WV/=^PB-2T7"U)<UU<M^FR<=_KX-=_RHUTR; LCQCG>=:-PMB2
M>6YPDN+:0G70>]L\78BM.T%'8JI6QEVKWA7AGV/]-IP.I:'GZ=6<UYF,OWXU
MI_U+?'V>DL<NKZE:CJ.IX^@FMHA:G'>K[?YS_MH*L=ZOM_G/^V@JQWJ^W^<_
M[:"K)>QV:^Y-<F;/C]LG7BYR".ZA0&7'W="=.\<((;893])QQ24)ZS6.Y=MV
M8>9=DHP7%FSAX69J.1'$P+4[V3+=&*J^]\$O2Z(W4VW\)[#(CW7<R=[XYHEQ
M&*VJ2M,5LZ\W=W:ZM\KDDCH4U'Y4=1<57/9>N2=;>&J+ZSW^I</7\A['T]\+
M814<GJ.?-+?Y$&^5>B<UO],8;/XF;D6VW0+/"C6VUPXUOM\-I+$2%#:2Q&C,
MHUY6VFTC1*1KYR>)XUS\I2G)SFVY-[6SURQBV,6S'&QH1A8@J1C%427H2+LL
MWL2/KM_>JK!<WHD,94C+O)YIUQE8<:6I"P--4GJ/41Q!%8S8)R/=PLA,GU%#
M@'4Z\IUZ2I(]GY-1YJ F$KY@%)5S)/$$'4$>0B@.=3VGTF@&I[3Z30#4]I])
MH#B@% * 4 H!0"@% * 4 H!0"@% /]U 6QE62V;';7*=NDQ#2UQG"S$;T=F/
M\- &XZ3S<I/TE<J/+62W:N77X%5=IJ9>=BX4:Y$J.FQ;Y/N7T[C5#)=S+Q>
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MH+<)2%)!/>J3Y>'DJ2A<EY48K8J''7\*T\Z[=N>)N;:7!;>SB5?      :
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M2>9L<.]3J4\?ND\2CHZ_30%&4E/3IQH#B@% * 4 H!0"@% * 4 H!0"@% *
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M'M37G)]C"@% * 4 H!0"@% * 4 H",N70SYU_,F@(J@% * 4!1.>VKST!\4
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M) "0 !U"A5;S1#._XWRS]NS_ ,<JNCQOR\/L+V'C^K_W7)_K2]I:M9R-% *
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M\*XIXZ2WQV/Z/F/*NHL6>+JMR4O<NOGB^VN_Y'6OJ,=5MD&* 4 H!0"@% *
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MN\^,/A!UWEXWQBPNN-4M:G9L=8Y>;CY$\BS.WB+S+BGIJQ[TER77#D5N7*_
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M H!0&T.U_P#!D'],N?\ BE5$9GYA]R]AWF@_VR/VI>TR!6L3(H!0"@% * 4
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MHNFVLE2R<A<T$Z*/"JWM]M*[C-"$(:0EMM*&VT )0VA*4(0D#@E"$@)2D =
MJ,DZNIUJ2BE%445P6Q%=%@R9AT8;)2/:=5ZK2./6K3B?(-35K:6\S6K-R\Z0
M6SMX%U0K+%BD..@2']!ZRQ^#2?ZC?0=#UG6L<KDFJ<"3LXENV^9^*?IW?(3-
M6&V* 4!]HZ?D_I% =M * <1Q!T(.H/\ +KH":M\MQQ7<.DJ]75M1Z>'2DGKX
M<=30$M0"@% * 4 H!0$-)_MW/./O10'10"@% * 4 H!0"@,8WZT.0)+DA"%*
MAOK4M"TI.C2U'532^GE 4?5/016Y:N*2H_>1 Y>-*S/FBGY;^;T%O=%9C4%
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G\4 H!0"@% =B.D]O\M: [* 4 H"NMWYTCZJ_O30%Q4 H!0"@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g83358top_new.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g83358top_new.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ /@+& P$1  (1 0,1 ?_$ ,@  0 !!0$! 0$
M       % 00&!P@# @D* 0$  @,! 0$             ! 4" P8!!P@0  $#
M P %!P4*"@@& P    $  @,1! 4A,5$2!D%A<9&A$P?1(E+2%(&QP3)RHC-S
M%0A"8H*RPB-#)#0VDE-C@[-TM!94)35UM79%%S<1  (! P$#!PD$"0(' 0
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MXM;A@E@FC.\R2-VIPY1S@Z0=!4)IQ;C+1HZ.W<MWK:NVFI6Y+1GNO#,( @"
MRS# BR)(T.E?3GIN5/14("40! $ 0! $ 0! $ 0! $!&9+5#TO\ >:@(I $
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MCIL-)#>=VZ:.9W>&WNGVDA8.ZT@/<5KM\+N7I.%J2;2KKIZ"7F^/,3!L1O\
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M*C\124;:=-?8<GXA\7X/AZ]'%NVKEW*E#>2C1))MI5D^E/8F<N<0?>[X[O\
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MNOA7[S>$S%]88S.<.7^(N;^[MK*.ZL+F+)6+9[J5D$3I&2-M;R.,RO )#9"
M:J#=X9."<K<E));'H_8=/@>.,7)NPL95F=NY.2BG%J2JW1<B=.LZ@H:D4T@D
M&FFA&@ZN=59W!0@C6*=* ( @" \I(8I122-C_E-![=: L)<1:2:6A\1_$-1S
M^:_>'O("/EPD@TQ3,=HU/!:3[HW@@(^3'WD5=Z!Y Y64>.GS:H"SH:TH:[.5
M $ 0! $ 0! $ 0%S%9W4VED$A'I;M&Z336X@40$A'A;AWTDD<8V"KW=E&]J
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MB_$V_P!SUL_0?^'=."YB6SZJ/W$=UKGCZ\$ 0! $!4:CT?"$ .L])]] 40!
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MC+^>SO. ?ED/++[S,]48N0@" ( @" ( @" ( @" ( @" ( @" ( @/ES&/\
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&:.9 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
